创业至今,窦■玲一直专注于医药事业,通过对市场敏锐的观察,益佰制药在制药领域细分市场表现的很突出,在国内市场,公司旗下止咳类、心脑血管类、抗肿瘤类等药品的占有率均名列前茅。根据发布的2010年三季报显示,益佰制药1～9月实现公司净利润约1.4亿元,同比增长70.44%,显示出良好发展势头。 Since its establishment, Dou Ling has been focusing on the pharmaceutical industry. Through its keen observation of the market, Yijing Pharmaceutical has performed prominently in the pharmaceutical market segment. In the domestic market, the company’s cough, cardio-cerebral vascular, and anti-tumor drugs The share of such drugs is among the best. According to the third quarterly report published in 2010, Yihe Pharmaceutical achieved a net profit of approximately RMB 140 million from January to September, an increase of 70.44% year-on-year, indicating a good momentum of development.